This rationale supports artificial reconstruction of the immune synapse by forcibly bridging NKG2D-CAR-engineered NK cells to EGFR/ERBB2-positive tumor cells, thereby overcoming immune escape and addressing intratumoral heterogeneity (Figure 7). The gene discussed is EGFR; the disease is neoplasm.